Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies

Stephen A. Luebker, Scott A. Koepsell

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

BRAF inhibitor therapy may provide profound initial tumor regression in metastatic melanoma with BRAF V600 mutations, but treatment resistance often leads to disease progression. A multi-center analysis of BRAF inhibitor resistant patient tissue samples detected genomic changes after disease progression including multiple secondary mutations in the MAPK/Erk signaling pathway, mutant BRAF copy number gains, and BRAF alternative splicing as the predominant putative mechanisms of resistance, but 41.7% of samples had no known resistance drivers. In vitro models of BRAF inhibitor resistance have been developed under a wide variety of experimental conditions to investigate unknown drivers of resistance. Several in vitro models developed genetic alterations observed in patient tissue, but others modulate the response to BRAF inhibitors through increased expression of receptor tyrosine kinases. Both secondary genetic alterations and expression changes in receptor tyrosine kinases may increase activation of MAPK/Erk signaling in the presence of BRAF inhibitors as well as activate PI3K/Akt signaling to support continued growth. Melanoma cells that develop resistance in vitro may have increased dependence on serine or glutamine metabolism and have increased cell motility and metastatic capacity. Future studies of BRAF inhibitor resistance in vitro would benefit from adhering to experimental parameters that reflect development of BRAF inhibitor resistance in patients through using multiple cell lines, fully characterizing the dosing strategy, and reporting the fold change in drug sensitivity.

Original languageEnglish (US)
Article number268
JournalFrontiers in Oncology
Volume9
Issue numberMAR
DOIs
StatePublished - Jan 1 2019

Fingerprint

Melanoma
Receptor Protein-Tyrosine Kinases
Disease Progression
Mutation
Genetic Models
Alternative Splicing
Glutamine
Phosphatidylinositol 3-Kinases
Serine
Cell Movement
Cell Line
In Vitro Techniques
Clinical Studies
Therapeutics
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • BRAF inhibitor
  • Cell line
  • Dabrafenib
  • Drug resistance
  • Invasion
  • Melanoma
  • Metabolism
  • Vemurafenib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies. / Luebker, Stephen A.; Koepsell, Scott A.

In: Frontiers in Oncology, Vol. 9, No. MAR, 268, 01.01.2019.

Research output: Contribution to journalReview article

@article{f636e7917a4b4637a180759995f9ab7f,
title = "Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies",
abstract = "BRAF inhibitor therapy may provide profound initial tumor regression in metastatic melanoma with BRAF V600 mutations, but treatment resistance often leads to disease progression. A multi-center analysis of BRAF inhibitor resistant patient tissue samples detected genomic changes after disease progression including multiple secondary mutations in the MAPK/Erk signaling pathway, mutant BRAF copy number gains, and BRAF alternative splicing as the predominant putative mechanisms of resistance, but 41.7{\%} of samples had no known resistance drivers. In vitro models of BRAF inhibitor resistance have been developed under a wide variety of experimental conditions to investigate unknown drivers of resistance. Several in vitro models developed genetic alterations observed in patient tissue, but others modulate the response to BRAF inhibitors through increased expression of receptor tyrosine kinases. Both secondary genetic alterations and expression changes in receptor tyrosine kinases may increase activation of MAPK/Erk signaling in the presence of BRAF inhibitors as well as activate PI3K/Akt signaling to support continued growth. Melanoma cells that develop resistance in vitro may have increased dependence on serine or glutamine metabolism and have increased cell motility and metastatic capacity. Future studies of BRAF inhibitor resistance in vitro would benefit from adhering to experimental parameters that reflect development of BRAF inhibitor resistance in patients through using multiple cell lines, fully characterizing the dosing strategy, and reporting the fold change in drug sensitivity.",
keywords = "BRAF inhibitor, Cell line, Dabrafenib, Drug resistance, Invasion, Melanoma, Metabolism, Vemurafenib",
author = "Luebker, {Stephen A.} and Koepsell, {Scott A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fonc.2019.00268",
language = "English (US)",
volume = "9",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

TY - JOUR

T1 - Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies

AU - Luebker, Stephen A.

AU - Koepsell, Scott A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - BRAF inhibitor therapy may provide profound initial tumor regression in metastatic melanoma with BRAF V600 mutations, but treatment resistance often leads to disease progression. A multi-center analysis of BRAF inhibitor resistant patient tissue samples detected genomic changes after disease progression including multiple secondary mutations in the MAPK/Erk signaling pathway, mutant BRAF copy number gains, and BRAF alternative splicing as the predominant putative mechanisms of resistance, but 41.7% of samples had no known resistance drivers. In vitro models of BRAF inhibitor resistance have been developed under a wide variety of experimental conditions to investigate unknown drivers of resistance. Several in vitro models developed genetic alterations observed in patient tissue, but others modulate the response to BRAF inhibitors through increased expression of receptor tyrosine kinases. Both secondary genetic alterations and expression changes in receptor tyrosine kinases may increase activation of MAPK/Erk signaling in the presence of BRAF inhibitors as well as activate PI3K/Akt signaling to support continued growth. Melanoma cells that develop resistance in vitro may have increased dependence on serine or glutamine metabolism and have increased cell motility and metastatic capacity. Future studies of BRAF inhibitor resistance in vitro would benefit from adhering to experimental parameters that reflect development of BRAF inhibitor resistance in patients through using multiple cell lines, fully characterizing the dosing strategy, and reporting the fold change in drug sensitivity.

AB - BRAF inhibitor therapy may provide profound initial tumor regression in metastatic melanoma with BRAF V600 mutations, but treatment resistance often leads to disease progression. A multi-center analysis of BRAF inhibitor resistant patient tissue samples detected genomic changes after disease progression including multiple secondary mutations in the MAPK/Erk signaling pathway, mutant BRAF copy number gains, and BRAF alternative splicing as the predominant putative mechanisms of resistance, but 41.7% of samples had no known resistance drivers. In vitro models of BRAF inhibitor resistance have been developed under a wide variety of experimental conditions to investigate unknown drivers of resistance. Several in vitro models developed genetic alterations observed in patient tissue, but others modulate the response to BRAF inhibitors through increased expression of receptor tyrosine kinases. Both secondary genetic alterations and expression changes in receptor tyrosine kinases may increase activation of MAPK/Erk signaling in the presence of BRAF inhibitors as well as activate PI3K/Akt signaling to support continued growth. Melanoma cells that develop resistance in vitro may have increased dependence on serine or glutamine metabolism and have increased cell motility and metastatic capacity. Future studies of BRAF inhibitor resistance in vitro would benefit from adhering to experimental parameters that reflect development of BRAF inhibitor resistance in patients through using multiple cell lines, fully characterizing the dosing strategy, and reporting the fold change in drug sensitivity.

KW - BRAF inhibitor

KW - Cell line

KW - Dabrafenib

KW - Drug resistance

KW - Invasion

KW - Melanoma

KW - Metabolism

KW - Vemurafenib

UR - http://www.scopus.com/inward/record.url?scp=85066618449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066618449&partnerID=8YFLogxK

U2 - 10.3389/fonc.2019.00268

DO - 10.3389/fonc.2019.00268

M3 - Review article

C2 - 31058079

AN - SCOPUS:85066618449

VL - 9

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - MAR

M1 - 268

ER -